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a b s t r a c t
We present a case of a 30-year-old Polish female who presented with increasing for about 2
years spastic paraparesis and urinary incontinence. She denied any risky sexual behaviors,
drug abuse, there was no history of surgery or blood transfusions. MRI of the brain showed
diffuse, hyperintensive in T2, poorly deﬁned lesions in the white matter. About 3 months later
paraparesis increased and control MRI showed progression of previously described lesions.
She was then diagnosed with HIV infection. There was a suspicion of progressive multifocal
leucoencephalopathy (PML) or vacuolar myelopathy in the course of HIV infection. Antiretro-
viral treatment was initiated leading, together with rehabilitation, to a progressive improve-
ment of symptoms. Pathological lesions on brain MRI completely disappeared. In conclusion,
HIV test should be done in every patient with neurological signs of unknown cause.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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According to the World Health Organization, since the
beginning of the epidemic in 1985, almost 70 million people
have been infected with HIV (human immunodeﬁciency virus)
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the Polish National Health Institute – National Institute of
Hygiene, since 1985 till the end of November 2013, there have
been 17 389 infected individuals in Poland: 3022 have been
diagnosed with AIDS and 1237 have died. Disorders of the
peripheral and central nervous system develop in over half of
the infected individuals [1]. There are two major groups ofniversity, Jaczewskiego 8, 20-954 Lublin, Poland.
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Fig. 1 – MRI of the brain (FLAIR weighted image): diffuse,
hyperintensive, poorly defined lesions in semioval center,
paraventricularly, at the back of the trunks of the lateral
ventricles, without contrast enhancement, an atrophical
enlargement of cerebral ventricles.
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patients – primary neurological disorders and opportunistic
infections. Progressive multifocal leukoencephalopathy (PML)
is an opportunistic infection that is the third most common
cause of neurological symptoms in HIV-infected patients, after
Toxoplasma encephalitis and HIV-associated neurocognitive
disorder (HAND) [2]. Neurological symptoms rarely occur as
early signs of AIDS. That is why if a patient is not in a group at
risk of HIV infection, diagnosis in this direction is often
omitted. It leads to the delay of both diagnosis and introduc-
tion of an appropriate treatment of potentially reversible
neurological deﬁcits. In Polish literature there are no case
reports concerning neurological presentation of HIV infection
that is why we decided to present this problem.
2. Case report
A 30-year-old Polish white female was admitted because of
increasing for about 2 years spastic paraparesis and urinary
incontinence (treated with oxybutynin). She was married,
childless, lived in the country, had secondary education and
was denying any risky sexual behaviors and drug addiction.
There was no history of surgery or blood transfusions. Her
problems began in 2008 when erythema on the cheeks
occurred, increasing after sunlight. There was a suspicion of
rosacea, but skin lesions withdrew without any treatment. In
April 2009 she suffered from pain of upper limbs, since
September 2009 she has had pain of the right lower limb. In the
anamnesis there has been a history of recurrent depressive
disorders treated for 2 years with citalopramum and second-
ary amenorrhea for 6 months. The patient connected all these
complaints with severe stress (death of her father, departure
abroad). In the laboratory results there has been thrombocy-
tosis and high ESR since 2008. In the examination the presence
of tumor-like lesion on the right side of her neck, tonsils
enlargement, stomach pain and periodically – liver enlarge-
ment, were observed. In March 2010 she was hospitalized in
the department of internal diseases where connective tissue
diseases were excluded. Because spastic paresis of lower limbs
was the main symptom, she was hospitalized in neurological
department outside our hospital, with the suspicion of
multiple sclerosis, however MRI of the brain and cervical
spinal cord did not reveal any abnormalities. As she was
admitted to our Department in August 2010 in neurological
examination there was spastic paraparesis, more pronounced
on the right side, with bilateral Babinski sign, no touch
disorders, walk with one-side help. She also complained of
memory problems, anxiety and difﬁculties with concentration.
In her laboratory results at the time of presentation in our
Department:
Basic laboratory panel showed high ESR ("91, 81 mm/h), CRP
– normal, in morphology: WBC = 9.28, 6.94, RBC = 3.78, 3.89,
HGB = 9.6, 10, MCV = 77.6, 80.5, PLT = "573, "659. There was
anemia of chronic diseases: iron: #15 mg/dl (normal level: 50–
170); transferrin: #106 mg/dl (normal level: 250–380); ferritin:
"581 ng/ml (normal level = 10–291). In urinary sediment: leuko-
cytes-countless, bacteria-multiple; in urine culture: doubtful
result, mixed bacteria. Vit. B12 level was normal, there was no
pathology of coagulation; liver, and kidney function tests werenormal. In the CSF: cytosis-12 cells/ml, protein = 60 mg/dl,
glucose = 53 mg/dl, oligoclonal bands were negative.
Autoimmune lab tests showed polyclonal gammapathy
(immunoglobulins IgA, IgG, IgM – increased), C3 and C4 –
normal, Ab against Borrelia burgdorferi – negative in the
blood and in the CSF, RF, ANA, ANCA – negative, beta-2-
microglobulin = "6.5 mg/l (normal level 0.7–1.8), Ca125, CA 15–
3, CA 19–9, CEA, AFP – normal, the Wassermann test – negative,
CMV IgM – negative, IgG – positive, EBV IgM – negative, IgG –
positive, HSV IgM – negative, IgG – positive.
Neurophysiological examinations. Visual evoked potentials
revealed prolonged to 120–124 ms latency of P100 bilaterally, in
EMG there were features of neurogenic process in distal parts
of the limbs.
Radiological results. In the X-ray of the chest pleural effusion
on the right side was noticed (it disappeared in the control X-
ray), ultrasonography of abdomen and gynecologic ultraso-
nography were normal, in neck ultrasonography there were
multiple augmented (to 15 mm) lymph nodes on both sides.
On MRI of the cervical, thoracic, lumbo-sacral region of the
spinal cord and spinal cone – there was no pathology, whereas
MRI of the brain showed diffuse, hyperintensive in T2, poorly
deﬁned lesions in semioval center, paraventricularly, at the
back of the trunks of the lateral ventricles, without contrast
enhancement, an atrophical enlargement of cerebral ventri-
cles and cortico-subcortical atrophy (Fig. 1).
About 3 months later paresis of lower limbs increased, she
needed walker aid and control MRI of the brain showed
progression of previously described lesions (Fig. 2). Antibodies
against HIV1/HIV2 were present, conﬁrmatory test (Western
blot) was positive, sgp120, gp 41, p31 were present. There was a
suspicion of PML or vacuolar myelopathy in the course of HIV
infection.
Fig. 2 – MRI of the brain (FLAIR weighted image), 3 months
later: progression of previously described lesions.
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to ARV scheme: lamivudine, tenofovir, darunavir, ritonavir.
Then due to increase in the number of HIV RNA copies
in serum (84 copies per ml) the pharmacotherapy wasFig. 3 – Control MRI of the brain (FLAIR weighted image),
1 year later: disappearance of previously described lesions.intensiﬁed with introduction of maraviroc. The treatment
regimen together with rehabilitation lead to progressive
improvement of symptoms: paraparesis decreased and the
patient was able to walk with nordic-walking sticks. The MRI
of the brain conducted about 10 months later normalized
and pathological paraventricular lesions completely disap-
peared (Fig. 3). Along with treatment continuation, neuro-
logical status of the patient recovered and ﬁnally she does
not use any walking aids.
3. Discussion
HIV positive patients present initially with neurological
symptoms in about 10–20% and about 40–60% of these patients
develop neurological manifestation in the course of the
disease [3,4]. Brain disease that is caused by HIV itself includes
HAND syndrome that, according to neuropsychological test-
ing, can be divided into three categories: asymptomatic
neurocognitive disorder, mild neurocognitive disorder (MND)
and HIV-associated dementia (HAD). Brain MRI in HAND
syndrome may show leukoencephalopathy and generalized
cerebral atrophy [5]. Our patient presented problems with
memory and concentration but otherwise did not have any
other problems with cognition. Poor performance in two or
more domains on neuropsychological or mental status testing
in a patient who does not report or demonstrate cognitive
decline is classiﬁed as asymptomatic neurocognitive im-
pairment [5].
Diseases that are caused by infectious, autoimmune and
neoplasmatic processes secondary to immunodeﬁciency in
the course of HIV infection include progressive multifocal
leucoencephalopathy (PML), toxoplasmosis, CNS lymphoma,
fungal infections (e.g. cryptococcal meningitis), tuberculous
meningitis, cerebrovascular diseases, neurocysticercosis and
cytomegalovirus encephalitis. Because of clinical picture and
the results of additional studies (blood, CSF, brain MRI) the
most probable (but not conﬁrmed) diagnosis seems to be
PML.
PML is an infection of oligodendrocytes caused by an
endogenous reactivation of the JC-virus (John Cunningham
virus – from the ﬁrst identiﬁed patient), a human polyoma-
virus belonging to papovaviridae family. This reactivation
takes place during states of immunosuppression including
AIDS, neoplasms, leukemia, in transplant recipients and also
in patients receiving HAART (in the period of immune
recovery) and monoclonal antibodies such as natalizumab
(used in the treatment of multiple sclerosis and Crohn's
disease) [6], rituximab (used in lupus) [7] and efalizumab
(used for the treatment of psoriasis) [8–10]. PML is character-
ized by the presence of widespread demyelinative lesions of
the CNS [11]. Neuroimaging studies in PML reveal typically
bilateral, asymmetrically distributed, conﬂuent, predomi-
nantly subcortical white matter lesions, located close to the
gray-white matter junction and in the periventricular region.
They show high signal intensity on T2 weighted imaging and
low signal intensity on T1 weighted imaging [12]. In our
patient such diffuse lesions were observed in semioval
center, paraventricularly and at the back of the trunks of the
lateral ventricles; there was also hydrocephalus ex vacuo and
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have been also taken under consideration in differential
diagnosis, is characterized by the presence of MRI changes
in the spinal cord–atrophy or intrinsic cord signal abnormal-
ities: T2-hyperintensive symmetric nonenhancing areas,
that may be conﬁned to the posterior columns, especially
the gracile tracts, or may be diffuse; they result from
extensive vacuolation [13]. In our case, there were no
pathologies in the spinal cord and the lesions in the brain
were suggestive of leukoencephalopathy, particularly of
PML.
Clinically PML can manifest as almost any neurological
symptom as it may localize in any part of the brain. PML is
characterized by an insidious onset and steady progression of
symptoms, like in a described case. Weakness, paresis, apathy,
ataxia, dysarthria and confusion are reported more frequently
than others [14]. In our patient paraparesis with urinary
incontinence was the leading symptom but she also com-
plained of cognition problems.
In the described case we did not establish the etiological
factor of brain lesions in the course of HIV infection. It may
be called a probable PML because there were clinical and
imaging features of the disease but neither CSF examination
as to the presence of JCV DNA nor histopathology with
demonstration of JCV DNA/protein were done [15]. In
HIV infection antiretroviral therapy is the principal ap-
proach in case of PML and neurological and radiological
improvement in our patient after 10 months of antiretroviral
treatment duration could conﬁrm the suspicion of the
disease [16].
We should always remember about the possibility of HIV
infection – our patient has not been diagnosed until 2 years of
symptoms onset although she had been hospitalized previ-
ously in internal diseases departments. In conclusion, a HIV
test should be done in every patient with neurological signs of
unknown cause. It can enable effective treatment when HIV
infection is diagnosed.
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